Niclosamide-BAY2353-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemENiclosamideCat.No.:HY-B0497CASNo.:50-65-7Synonyms:BAY2353分?式:C??H?Cl?N?O?分?量:327.12作?靶點:STAT;Parasite;Antibiotic作?通路:JAK/STATSignaling;StemCell/Wnt;Anti-infection儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMF:5mg/mL(15.28mM;Needultrasonic)DMSO:4.55mg/mL(13.91mM;Needultrasonic)H2O:<0.1mg/mL(ultrasonic;warming;heatto60°C)(insoluble)MassSolvent1mg5mg10mgConcentration制備儲備液1mM3.0570mL15.2849mL30.5698mL5mM0.6114mL3.0570mL6.1140mL10mM0.3057mL1.5285mL3.0570mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMF>>40%PEG300>>5%Tween-80>>45%salineSolubility:0.5mg/mL(1.53mM);Suspendedsolution;Needultrasonic2.請依序添加每種溶劑：20%HP-β-CD>>5%CremophorELSolubility:5mg/mL(15.28mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Niclosamide(BAY2353)?種具有?服活性的?于寄??感染研究的抗蠕?化合物。NiclosamideSTAT3抑制劑，在HeLa細(xì)胞中的IC50為0.25μM。Niclosamide具有抗癌的?物活性，并能抑制VeroE6細(xì)胞的DNA復(fù)制。IC50&TargetSTAT30.25μM(IC50,inHeLacells)體外研究Niclosamide(0.6nM-46μM)treatmentinhibitsadrenocorticalcarcinomacellularproliferationinBD140A,SW-13,andNCI-H295Rcells[3].Niclosamide(0.05-5μM,24h)treatmentinhibitsSTAT3-mediatedluciferasereporteractivityinHeLacells[4].Niclosamide(10μM)treatmentinhibitsvirusreplicationinVeroE6cells[5].CellViabilityAssay[3]CellLine:BD140A,SW-13andNCI-H295RcellsConcentration:0.6nM-46μMIncubationTime:Result:InhibitedcellularproliferationinadrenocorticalcarcinomacelllineswiththeIC50of0.12μM,0.15μM,and0.53μMinBD140A,SW-13,andNCI-H295R,respectively.CellViabilityAssay[4]CellLine:HelacellsConcentration:0.05-5μMIncubationTime:24hoursResult:InhibitedSTAT3-mediatedluciferasereporteractivitywithanIC50of0.25μM.CellViabilityAssay[4]CellLine:VeroE6cells[5]Concentration:10μM2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEIncubationTime:2daysResult:InhibitedthesynthesisofviralantigensofSARS-CoVinVeroE6cells.體內(nèi)研究Niclosamide(oralgavage;100mg/kg,200mg/kg;onceaweek;8weeks)treatmentinhibitsadrenocorticalcarcinomatumorgrowthinvivo[3].AnimalModel:Nu+/Nu+miceinjectedwithNCI-H295Rcells[3]Dosage:100mg/kg,200mg/kgAdministration:Oralgavage;100mg/kg,200mg/kg;onceaweek;8weeksResult:Showeda60%-80%inhibitionintumorgrowth,ascomparedtothecontrolgroup.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?CellRes.2022Jun;32(6):513-529.?EmergMicrobesInfect.2022Dec;11(1):483-497.?CellSyst.2018Apr25;6(4):424-443.e7.?AntiviralRes.January2022,105228.?CellDeathDis.2022Feb3;13(2):112.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].PAndrews,etal.Thebiologyandtoxicologyofmolluscicides,Bayluscide.PharmacolTher.1982;19(2):245-95.[2].WeiChen,etal.Niclosamide:Beyondanantihelminthicdrug.CellSignal.2018Jan;41:89-96.[3].KeiSatoh,etal.IdentificationofNiclosamideasaNovelAnticancerAgentforAdrenocorticalCarcinoma.ClinCancerRes.2016Jul15;22(14):3458-66.[4].XiaomeiRen,etal.IdentificationofNiclosamideasaNewSmall-MoleculeInhibitoroftheSTAT3SignalingPathway.ACSMedChemLett.2010Sep7;1(9):454-9.[5].Chang-JerWu,etal.Inhibitionofsevereacuterespiratorysyndromecoronavirusreplicationbyniclosamide.AntimicrobAgentsChemother.2004Jul;48(7):2693-6.McePdfHeightCauti